<DOC>
	<DOC>NCT01068860</DOC>
	<brief_summary>This was a 10-week, placebo-controlled, randomized study to investigate the effect of injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or Type 2 Diabetes Mellitus (T2DM) already treated on different background diabetes therapies.</brief_summary>
	<brief_title>To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Troglitazone</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<mesh_term>Acetohexamide</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>1. Patient must fulfill all criteria in one of the following groups: Impaired Glucose Tolerance (IGT) as diagnosed per protocol and not on an antidiabetic medicine during the study Diagnosis of Type 2 diabetes in stable treatment with metformin Diagnosis of Type 2 diabetes in stable treatment with metformin (at least 1000 mg/day) in combination with a sulfonylurea Diagnosis of Type 2 diabetes in stable treatment with metformin (at least 1000 mg/day), sulfonylurea and thiazolidinedione combination therapy Diagnosis of Type 2 diabetes in stable treatment with at least two insulin injections a day with or without metformin 2. HbA1c between 6.5% and 8%, inclusive, at Screening; this criterion does not apply to the IGT group 3. Age from 1874 years, inclusive, and of either sex 1. Type 1 diabetes or diabetes that is a result of pancreatic injury or other secondary forms of diabetes 2. History or current findings of active pulmonary disease (e.g. tuberculosis, fungal diseases) as defined in the protocol: 3. Known presence or suspicion of active or recurrent bacterial, fungal or viral infection at the time of enrollment proven.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>canakinumab</keyword>
	<keyword>Pre diabetic</keyword>
	<keyword>glucose intolerant</keyword>
	<keyword>oral anti diabetic medication</keyword>
	<keyword>insulin treatment</keyword>
	<keyword>metabolic syndrome</keyword>
</DOC>